Breast cancer progression is a highly orchestrated process that is much more than just acquisition of increased cellular proliferative capacity. The first step in the development of breast cancer, proliferation of epithelial cells into the central lumen, involves the acquisition by the cancer cells of the ability to evade structural and biochemical constraints imposed by cell-cell and cell-extracellular matrix interactions. Progression from early, proliferative disease through ductal carcinoma in situ to invasive breast cancer requires the ability to break down the basement membrane and to interact with the stromal extracellular matrix. The ultimate development of metastatic capability, the most deadly and least treatable stage of breast cancer progression, requires the cancer cells to separate from the parental tumor mass, to intravasate into and subsequently extravasate from the vasculature, and to settle and grow at a distant site. All of these steps, from initial breakdown of tissue structure, through increased invasiveness, and ultimate distribution throughout the body, are characteristic features of epithelial-mesenchymal transition (EMT), a developmental process in which adhesive epithelial cells acquire the motile and migratory characteristics of mesenchymal cells (1) . Both developmental and pathologic EMT are associated with dramatic alterations in patterns of gene expression, and recent studies have shown that a number of the transcription factors that regulate developmental EMT, including Snail, Slug, and Twist, are also activated during breast cancer progression (2).
Determination that transcription factors involved in early stages of development also become reactivated in tumors provides the possibility of entirely novel targets for therapeutic intervention. However, although there has been considerable recent research effort directed toward understanding how EMT is controlled during breast cancer progression, it is clear that our understanding of this process is still incomplete.
EMT as a source of cellular diversity
Apart from tissue morphogenesis, EMT in development plays an important first step in the generation of diverse cell and tissue types, as cells that have undergone EMT and migrated to different points within the body can redifferentiate into epithelial cells (a process known as mesenchymal-epithelial transition [MET]) or into other cell types (1). Gastrulation, the earliest EMT in development, results in the formation, from the ectoderm, of the mesoderm and the endoderm. The mesoderm contains precursors that give rise to muscle, bone, and connective tissues, while the endoderm ultimately differentiates into organs of the digestive and respiratory tract. EMT that occurs during neural crest delamination produces cells that act as precursors of neurons, melanocytes, bone, and connective tissues. Recent studies have shown that EMT may act in tumor development in a similar fashion, producing cells with stem/progenitor cell characteristics and an increased ability to differentiate into the variety of different cell types that compose the tumor (3) (4) (5) .
As the initiating cells that give rise to every different cell type in the body, stem cells have been extensively investigated for their role in embryonic development, but studies have shown that cells with stem/ progenitor cell properties may also play critical roles in tumor formation and progression (6) . Normal stem cells proliferate very slowly, exist as minority populations in defined niches within tissues, and have distinct responses to cytotoxic agents and other extracellular stimuli (7, 8) . In normal tissues, stem cells can give rise to other stem cells or to progenitor cells that further differentiate into the different cell types within the tissue. While it has been long suspected that some cancers may be derived from transformed stem cells, or that cancers might acquire the ability of stem cells to undergo limitless proliferation, it was not until 1994 that cells with these properties, designated "tumor-initiating cells" or "cancer stem cells" (CSCs), were first found in human acute myeloid leukemia (9) . Since this initial observation, cells with CSC characteristics have been found in solid tumors, including breast, brain, colon, and pancreas (10-14), and the evidence that CSCs possess both greatly enhanced tumorigenic capability and increased resistance to many cytotoxic therapies has greatly increased interest in how CSCs are derived and how therapeutic agents more effective for targeting CSCs might be identified (6) . Recent investigations using cultured human breast cancer cells (3, 4) and transgenic mice (5) Six1 stimulates mammary tumor progression through induction of EMT Homeobox (Hox) genes encode an extensive family of conserved transcription factors designated as homeoproteins, members of which have been implicated in nearly every step of embryonic development, controlling proliferation, cell death, and morphogenesis. Deregulation of Hox gene expression has been found in many cancer types, and while a direct causative relationship between increased expression and cancer development has not been identified for most Hox genes, those found to be upregulated in cancer are usually associated with poorly differentiated cell types during development (17) . Six1 is a homeoprotein that is essential for the development of a number of organs and is upregulated in proliferating precursor populations relative to differentiated adult tissues (18) . Six1 was first identified as upregulated in breast cancer cells in 1998 (18) . In the decade since, subsequent studies have shown that it may play a critical role in breast cancer development. Six1 shows increased expression in human breast cancer through gene amplification (18, 19) , and exogenous overexpression of Six1 in mammary cells is sufficient to induce malignant transformation and chromosomal instability (20) . Mechanistic insights come from the observation that overexpression of Six1 leads to abrogation of cell cycle checkpoints (18) . The current studies by McCoy et al. (15) and Micalizzi et al. (16) considerably extend these previous investigations by using mouse models to define how Six1 induces EMT to stimulate tumor development and metastasis (Figure 1) .
McCoy et al. (15) present evidence revealing how Six1 may function to promote tumors at the earliest stages of development through the use of new transgenic mice that inducibly express Six1 in mouse mammary epithelial cells. Expression of Six1 led to epithelial hyperplasia and alveolar expansion within the first few weeks. Sustained expression of Six1 led to the formation of aggressive tumors characterized by highly divergent epithelial differentiation that included regions displaying evidence of EMT. Six1 expression was also shown to increase the fraction of epithelial cells expressing mammary stem/progenitor characteristics: isolated primary epithelial cells from Six1-expressing mice showed increased expression of the stem/progenitor cell-associated cell surface markers CD24 and CD29, as well as greatly increased growth as mammospheres, an assay that reflects cell self-renewal. Thus, Six1-induced EMT was associated with increases in the population of stem/progenitor cells and spontaneous tumor growth. Micalizzi et al. (16) used a parallel approach to define how Six1-induced EMT facilitates tumor metastasis using xenograft assays. Overexpression of Six1 in cultured human mammary cells caused immediate morphological EMT, and Six1-overexpressing cells showed a greatly increased propensity for spontaneous metastasis in orthotopic xenografts, as well as substantially greater metastatic capability following intracardiac injection. Analysis of transcriptional alterations in Six1-overexpressing cells revealed the activation of a TGF-b response signature, and inhibition of TGF-b signaling in Six1-overexpressing cells greatly reduced their metastatic capability. Consistent with the concept that Six1 could act to promote metastasis in human tumors, analysis of publicly available datasets showed that increased expression of Six1 was predictive of decreased time to metastasis, relapse, and survival in breast cancer, and of poor prognosis in a number of other cancers.
Future directions
The current studies (15, 16) define a central role for Six1 in the development of diverse tumor types, provide insight into the role of Six1-induced EMT in tumor development, and point toward avenues of research with considerable potential. Six1, as a transcription factor that is little expressed in adult tissues except in tumors, represents an attractive therapeutic target, but selective inhibition of transcription factors can be challenging. However, the new mouse models developed for these studies could be particularly useful for testing and refining appropriately targeted inhibitors. Additionally, defining how Six1 increases the stem/progenitor cell population, and whether these increases are directly responsible for the subsequent tumor development, could provide insight into the stage of tumor development at which Six1 inhibition might be most effective. Similarly, determination of how Six1 activates TGF-b signaling in breast cells, whether through induction of TGF-b itself or through some alternate mechanism, could better define how Six1-induced metastasis might be targeted. Perhaps the most important question will be the extent to which the Six1-induced processes identified here are involved in human breast cancer development and how we can translate these findings for clinical benefit.
